Device Trial Radar · NCT03581877
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
31
Actual
Start
Jan 28, 2019
Primary completion
Mar 19, 2023
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Northwell HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)
Conditions
- Pulmonary Embolism
- Pulmonary Hypertension
- Thromboembolism
- Right Ventricular Dysfunction
Interventions
AlteplaseDrug
As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
EKOSDevice
As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Right ventricle (RV) to Left ventricle (LV) ratioTime frame: 48 hours
- Pulmonary pressuresTime frame: 48 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Southside Northwell Hospital
Bay Shore, New York
Long Island Jewish Medical Center
Queens, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.